Srinagar Magazine

Merkel Cell Carcinoma Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – Incyte Corporation, Kartos Therapeutics, Immunomic

 Breaking News
  • No posts were found

Merkel Cell Carcinoma Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – Incyte Corporation, Kartos Therapeutics, Immunomic

March 21
06:08 2023
Merkel Cell Carcinoma Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies - Incyte Corporation, Kartos Therapeutics, Immunomic
The Merkel Cell Carcinoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Merkel Cell Carcinoma pipeline products will significantly revolutionize the Merkel Cell Carcinoma market dynamics.

DelveInsight’s “Merkel Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Merkel Cell Carcinoma, historical and forecasted epidemiology as well as the Merkel Cell Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Merkel Cell Carcinoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Merkel Cell Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Merkel Cell Carcinoma Market Insights

 

Merkel Cell Carcinoma Overview

Merkel cell carcinoma (MCC) is a rare but highly aggressive skin cancer with neuroendocrine features. Merkel cell carcinoma carcinogenesis is associated either with the presence of clonally integrated Merkel cell polyoma-virus(MCPyV; also known as human polyomavirus (HPyV5)) or chronic ultraviolet light (UV) exposure.

 

Some of the key facts of the Merkel Cell Carcinoma Market Report: 

  • The Merkel Cell Carcinoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • As per “Skin Cancer Foundation”, Merkel cell carcinoma (MCC) is 40 times more rare than melanoma, with an estimated one case per 130,000 people in the US. Approximately 3,000 new cases are diagnosed annually in the U.S. Experts expect that this will increase to 3,250 cases diagnosed annually by 2025
  • Epidemiologic data suggest that there are approximately 2500 new Merkel cell carcinoma cases per year within the European Union (EU), and approximately 1000 of these patients will die from their disease. [Becker et al. 2017]
  • According to merkel cell .org, Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with roughly 2,000 new cases per year in the United States
  • As per the National Organization for Rare Disorders (NORD), approximately 60% of MCC tumors arises in men. Moreover, in the past 15 years, the incidence has tripled in the United States, and it can be lethal for about one-third of the people affected
  • Key Merkel Cell Carcinoma Companies: Incyte Corporation, Kartos Therapeutics, Immunomic Therapeutics, Neoimmunetech, and others
  • Key Merkel Cell Carcinoma Therapies: Retifanlimab, Navtemadlin(KRT-232), ITI-3000, NT-I7 (efineptakin alfa), and others
  • The Merkel Cell Carcinoma epidemiology based on gender analyzed that Merkel Cell Carcinoma affects males more than females

 

Get a Free sample for the Merkel Cell Carcinoma Market Report – 

https://www.delveinsight.com/sample-request/merkel-cell-carcinoma-market

 

Key benefits of the Merkel Cell Carcinoma Market report:

  1. Merkel Cell Carcinoma market report covers a descriptive overview and comprehensive insight of the Merkel Cell Carcinoma Epidemiology and Merkel Cell Carcinoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Merkel Cell Carcinoma market report provides insights on the current and emerging therapies.
  3. Merkel Cell Carcinoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Merkel Cell Carcinoma market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Merkel Cell Carcinoma market.

 

Download the report to understand which factors are driving Merkel Cell Carcinoma epidemiology trends @ Merkel Cell Carcinoma Epidemiological Insights 

 

Merkel Cell Carcinoma Market  

The dynamics of the Merkel Cell Carcinoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

 

Merkel Cell Carcinoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Merkel Cell Carcinoma Epidemiology Segmentation:

The Merkel Cell Carcinoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Merkel Cell Carcinoma
  • Prevalent Cases of Merkel Cell Carcinoma by severity
  • Gender-specific Prevalence of Merkel Cell Carcinoma
  • Diagnosed Cases of Episodic and Chronic Merkel Cell Carcinoma

 

Merkel Cell Carcinoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Merkel Cell Carcinoma market or expected to get launched during the study period. The analysis covers Merkel Cell Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Merkel Cell Carcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Merkel Cell Carcinoma market share @ Merkel Cell Carcinoma market forecast

 

Merkel Cell Carcinoma Therapies and Key Companies

  • Retifanlimab: Incyte Corporation
  • Navtemadlin(KRT-232): Kartos Therapeutics
  • ITI-3000: Immunomic Therapeutics
  • NT-I7 (efineptakin alfa): Neoimmunetech

 

Merkel Cell Carcinoma Market Strengths

  • Increased awareness and interest by government and various organizations

 

Scope of the Merkel Cell Carcinoma Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Merkel Cell Carcinoma Companies: Incyte Corporation, Kartos Therapeutics, Immunomic Therapeutics, Neoimmunetech, and others
  • Key Merkel Cell Carcinoma Therapies: Retifanlimab, Navtemadlin(KRT-232), ITI-3000, NT-I7 (efineptakin alfa), and others
  • Merkel Cell Carcinoma Therapeutic Assessment: Merkel Cell Carcinoma current marketed and Merkel Cell Carcinoma emerging therapies
  • Merkel Cell Carcinoma Market Dynamics: Merkel Cell Carcinoma market drivers and Merkel Cell Carcinoma market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Merkel Cell Carcinoma Unmet Needs, KOL’s views, Analyst’s views, Merkel Cell Carcinoma Market Access and Reimbursement 

 

Merkel Cell Carcinoma Market Opportunities

  • Competitors are less so that can act as opportunity for lead players to dominate the market

 

Table of Contents 

1. Merkel Cell Carcinoma Market Report Introduction

2. Executive Summary for Merkel Cell Carcinoma

3. SWOT analysis of Merkel Cell Carcinoma

4. Merkel Cell Carcinoma Patient Share (%) Overview at a Glance

5. Merkel Cell Carcinoma Market Overview at a Glance

6. Merkel Cell Carcinoma Disease Background and Overview

7. Merkel Cell Carcinoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Merkel Cell Carcinoma 

9. Merkel Cell Carcinoma Current Treatment and Medical Practices

10. Merkel Cell Carcinoma Unmet Needs

11. Merkel Cell Carcinoma Emerging Therapies

12. Merkel Cell Carcinoma Market Outlook

13. Country-Wise Merkel Cell Carcinoma Market Analysis (2019–2032)

14. Merkel Cell Carcinoma Market Access and Reimbursement of Therapies

15. Merkel Cell Carcinoma Market Drivers

16. Merkel Cell Carcinoma Market Barriers

17.  Merkel Cell Carcinoma Appendix

18. Merkel Cell Carcinoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Merkel Cell Carcinoma treatment, visit @ Merkel Cell Carcinoma Medications

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Related Articles